Amneal Pharmaceuticals, Inc. (AMRX)Healthcare | Drug Manufacturers - Specialty & Generic | Bridgewater, United States | NasdaqGS
19.04 USD
-0.21
(-1.091%) ⇩
(Oct. 16, 2026, 3:38 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 2:30 a.m. EDT
The investment case here is fractured between a compelling short-term catalyst and a fundamentally precarious balance sheet. On the short end, the company is clearly in the spotlight; the recent 4.7x run and fresh highs suggest the market is pricing in the success of the Kashiv deal and new FDA approvals. The options flow confirms this, with heavy call interest at strikes significantly above the current price, hinting that speculators expect a continued rally. However, this optimism clashes violently with the long-term reality. The stock is trading at a massive 193 times book value, a metric that screams overvaluation for a generic drug manufacturer. More concerning is the cash flow situation: the company is burning cash, with free cash flow in the negative hundreds of millions, while carrying nearly $2.8 billion in debt against a tiny equity base. This creates a fragile structure where any stumble in biosimilar growth could trigger a liquidity crisis. While the momentum is strong enough to justify a speculative entry now, the lack of a dividend, the debt load, and the extreme valuation multiples make this a dangerous hold for anything beyond a few months. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.153442 |
| AutoARIMA | 0.190324 |
| MSTL | 0.190880 |
| AutoETS | 0.190938 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 39% |
| H-stat | 12.62 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.393 |
| Excess Kurtosis | -0.81 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2386.528 |
| Revenue per Share | 9.866 |
| Market Cap | 6,631,556,608 |
| Trailing P/E | 38.86 |
| Forward P/E | 15.97 |
| Beta | 1.22 |
| Profit Margins | 5.05% |
| Website | https://www.amneal.com |
As of Oct. 10, 2026, 2:30 a.m. EDT: Speculators are positioning for volatility rather than a clear directional bet. Call open interest is heavily skewed out-of-the-money at the $22.50 strike, suggesting bets on a significant upside move, while put volume is concentrated at the $17.50 strike with notably elevated implied volatility, indicating hedging against a drop below current levels. The mix suggests a 'straddle' mentality where traders expect a large move regardless of direction, likely driven by upcoming catalysts like the FDA contrast options approval or earnings, rather than a consensus on immediate price appreciation.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.9405242 |
| Address1 | 400 Crossing Boulevard |
| Address2 | 3rd Floor |
| All Time High | 24.48 |
| All Time Low | 1.24 |
| Ask | 24.3 |
| Ask Size | 2 |
| Audit Risk | 3 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 3,830,770 |
| Average Daily Volume3 Month | 2,437,843 |
| Average Volume | 2,437,843 |
| Average Volume10Days | 3,830,770 |
| Beta | 1.218 |
| Bid | 13.72 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | 0.103 |
| City | Bridgewater |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 2 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 19.04 |
| Current Ratio | 2.205 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 19.385 |
| Day Low | 18.94 |
| Debt To Equity | 2,386.528 |
| Display Name | Amneal Pharmaceuticals |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,793,736,000 |
| Earnings Call Timestamp Start | 1,793,736,000 |
| Earnings Growth | 1.571 |
| Earnings Quarterly Growth | 1.572 |
| Earnings Timestamp | 1,793,709,000 |
| Earnings Timestamp End | 1,793,709,000 |
| Earnings Timestamp Start | 1,793,709,000 |
| Ebitda | 689,436,992 |
| Ebitda Margins | 0.22115 |
| Enterprise To Ebitda | 12.897 |
| Enterprise To Revenue | 2.852 |
| Enterprise Value | 8,891,867,136 |
| Eps Current Year | 1.02413 |
| Eps Forward | 1.19257 |
| Eps Trailing Twelve Months | 0.49 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 908 947 3146 |
| Fifty Day Average | 18.5412 |
| Fifty Day Average Change | 0.49880028 |
| Fifty Day Average Change Percent | 0.026902264 |
| Fifty Two Week Change Percent | 94.05242 |
| Fifty Two Week High | 21.175 |
| Fifty Two Week High Change | -2.1349983 |
| Fifty Two Week High Change Percent | -0.10082637 |
| Fifty Two Week Low | 9.765 |
| Fifty Two Week Low Change | 9.275001 |
| Fifty Two Week Low Change Percent | 0.9498208 |
| Fifty Two Week Range | 9.765 - 21.175 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,525,699,800,000 |
| Float Shares | 197,325,593 |
| Forward Eps | 1.19257 |
| Forward P E | 15.965521 |
| Free Cashflow | -115,327,128 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 8,700 |
| Fullday Change | -0.20999908 |
| Fullday Change Percent | -1.0909044 |
| Fullday Price | 19.04 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.39810002 |
| Gross Profits | 1,241,091,968 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.52099997 |
| Held Percent Institutions | 0.48580003 |
| Implied Shares Outstanding | 348,296,027 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Ipo Expected Date | 2,023-12-27 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with a focus on central nervous system and endocrine disorders, including Parkinson's disease. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT, which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey. |
| Long Name | Amneal Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 6,631,556,608 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_38444119 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 157,363,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 6,736,045,162 |
| Number Of Analyst Opinions | 7 |
| Open | 19.28 |
| Operating Cashflow | 200,778,000 |
| Operating Margins | 0.18335 |
| Overall Risk | 4 |
| Payout Ratio | 0.0 |
| Peg Ratio | 1.8 |
| Phone | 908 947 3120 |
| Previous Close | 19.25 |
| Price Eps Current Year | 18.59139 |
| Price Hint | 2 |
| Price To Book | 184.85437 |
| Price To Sales Trailing12 Months | 2.1271706 |
| Profit Margins | 0.050479997 |
| Quick Ratio | 1.375 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.42857 |
| Region | US |
| Regular Market Change | -0.20999908 |
| Regular Market Change Percent | -1.0909044 |
| Regular Market Day High | 19.385 |
| Regular Market Day Low | 18.94 |
| Regular Market Day Range | 18.94 - 19.385 |
| Regular Market Open | 19.28 |
| Regular Market Previous Close | 19.25 |
| Regular Market Price | 19.04 |
| Regular Market Time | 1,792,179,502 |
| Regular Market Volume | 1,036,153 |
| Return On Assets | 0.08597 |
| Return On Equity | 6.1301703 |
| Revenue Growth | 0.099 |
| Revenue Per Share | 9.866 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 3 |
| Shares Outstanding | 348,296,027 |
| Shares Percent Shares Out | 0.0324 |
| Shares Short | 11,278,967 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 10,571,834 |
| Short Name | Amneal Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.046 |
| Short Ratio | 4.13 |
| Source Interval | 15 |
| State | NJ |
| Symbol | AMRX |
| Target High Price | 27.0 |
| Target Low Price | 20.0 |
| Target Mean Price | 22.71429 |
| Target Median Price | 22.0 |
| Total Cash | 131,413,000 |
| Total Cash Per Share | 0.411 |
| Total Debt | 2,791,760,896 |
| Total Revenue | 3,117,548,032 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.49 |
| Trailing P E | 38.857143 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 15.324975 |
| Two Hundred Day Average Change | 3.715026 |
| Two Hundred Day Average Change Percent | 0.24241644 |
| Type Disp | Equity |
| Volume | 1,036,153 |
| Website | https://www.amneal.com |
| Zip | 8,807 |